Author

Philippe A. Gallay

Scripps Research InstituteORCID 0000-0002-6151-4764Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 2 Approach:statistical model· 1 Assay:structural biology· 1

Frequent Co-Authors

Daniel J. HadersiD· 2 shared Michael D. BobardtiD· 2 shared Sean M. Russell· 2 shared Tyler J. Umansky· 2 shared Virgil L. WoodsiD· 2 shared Adolfo García‐SastreiD· 1 shared Asha Z. GoodmaniD· 1 shared Audrey Thomson· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Daniel J. HadersORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MDL-001: an Oral, Direct-Acting Broad-Spectrum Antiviral for Influenza-Like Illness (ILI) and Chronic Hepatitis In Vivo

Virgil L. Woods, Tyler J. Umansky, Sean M. Russell, Asha Z. Goodman, Michael D. Bobardt, Briana Lynn McGovern, Romel Rosales, M. Luis Rodriguez, Harm van Bakel, Emilia Mia Sordillo, Viviana R. Simon, Adolfo García‐Sastre, Kris M. White, Philippe A. Gallay, Davey Smith, Daniel J. Haders

This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.

Pharmaceuticals · Oct 18, 2026Peer-reviewedPharmacology & Toxicology

The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral Development

Virgil L. Woods, Tyler J. Umansky, Sean M. Russell, Philippe A. Gallay, Davey Mitchell Smith, Daniel J. Haders

The paper identifies the RdRp Thumb-1 pocket as a conserved target for broad-spectrum antivirals, validated through structural and biochemical analyses of multiple viruses.

bioRxiv · Mar 29, 2024 · PreprintBioinformatics

Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2

Gary D. Ewart, Michael D. Bobardt, Bo Hjorth Bentzen, Yannan Yan, Audrey Thomson, Klaus Klumpp, Stephen L. Becker, METTE MARIE ROSENKILDE, Michelle Miller, Philippe A. Gallay

This paper shows that BIT225, an E-protein inhibitor, reduces disease severity and increases survival in SARS-CoV-2 infected mice when administered before or after infection.

PLoS Pathogens · Aug 7, 2023Peer-reviewedMolecular Biology